| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Rasagiline mesylate (USAN); Rasagiline mesilate (JAN); Azilect (TN) | ||||||||
| Product | AZILECT (Teva Neuroscience) | ||||||||
| Generic | RASAGILINE (Alvogen), RASAGILINE (Ascend Laboratories), RASAGILINE (AvKARE), RASAGILINE (Micro Labs Limited), RASAGILINE (NorthStar RxLLC), RASAGILINE (Teva Pharmaceuticals USA), RASAGILINE MESYLATE (Avet Pharmaceuticals), RASAGILINE MESYLATE (Mylan Pharmaceuticals) | ||||||||
| Formula | C12H13N. CH4SO3 | ||||||||
| Exact mass | 267.0929 | ||||||||
| Mol weight | 267.344 | ||||||||
| Structure |  | ||||||||
| Class | Neuropsychiatric agent DG01568 MAO inhibitor DG01512 Monoamine oxidase B inhibitor DG01967 Antiparkinson agent Metabolizing enzyme substrate DG01892 CYP1A2 substrate | ||||||||
| Remark |
| ||||||||
| Efficacy | Antiparkinsonian, Monoamine oxidase B (MAO-B) inhibitor | ||||||||
| Disease | Parkinson's disease [DS:H00057] | ||||||||
| Target | MAOB [HSA:4129] [KO:K00274] | ||||||||
| Pathway |
| ||||||||
| Metabolism | Enzyme: CYP1A2 [HSA:1544] | ||||||||
| Interaction | |||||||||
| Structure map |
| ||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N04 ANTI-PARKINSON DRUGS N04B DOPAMINERGIC AGENTS N04BD Monoamine oxidase B inhibitors N04BD02 Rasagiline D02562 Rasagiline mesylate (USAN) <JP/US> USP drug classification [BR:br08302] Antiparkinson Agents Monoamine Oxidase B (MAO-B) Inhibitors Rasagiline D02562 Rasagiline mesylate (USAN) Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 116 Antiparkinsonian agents 1169 Others D02562 Rasagiline mesylate (USAN); Rasagiline mesilate (JAN) Drug groups [BR:br08330] Neuropsychiatric agent DG01568 MAO inhibitor DG01512 Monoamine oxidase B inhibitor DG00865 Rasagiline D02562 Rasagiline mesylate DG01967 Antiparkinson agent DG00865 Rasagiline D02562 Rasagiline mesylate Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG00865 Rasagiline D02562 Rasagiline mesylate Drug classes [BR:br08332] Neuropsychiatric agent DG01967 Antiparkinson agent D02562 Rasagiline mesylate Target-based classification of drugs [BR:br08310] Enzymes Oxidoreductases (EC1) Amine oxidases MAOB D02562 Rasagiline mesylate (USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D02562 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D02562 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D02562 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D02562 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D02562 Drug groups [BR:br08330] Neuropsychiatric agent DG01568 MAO inhibitor DG01512 Monoamine oxidase B inhibitor DG00865 Rasagiline DG01967 Antiparkinson agent DG00865 Rasagiline Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG00865 Rasagiline | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 18 1 C8y C 19.8358 -20.6271 2 C8y C 19.8358 -19.2233 3 C8x C 18.6201 -18.5214 4 C8x C 17.4042 -19.2233 5 C8x C 17.4042 -20.6271 6 C8x C 18.6201 -21.3291 7 C1y C 21.1709 -21.0609 8 C1x C 21.9961 -19.9252 9 C1x C 21.1709 -18.7895 10 N1b N 21.1694 -22.4521 11 C1b C 22.3845 -23.1554 12 C3b C 23.5851 -22.4638 13 C3a C 24.7493 -21.7502 14 O1d O 30.5752 -19.7146 15 S4a S 30.5752 -21.1185 16 C1a C 29.1714 -21.1185 17 O1d O 31.9791 -21.1185 18 O1d O 30.5752 -22.5223 BOND 18 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 1 7 1 8 7 8 1 9 8 9 1 10 2 9 1 11 7 10 1 #Up 12 10 11 1 13 11 12 1 14 12 13 3 15 14 15 2 16 15 16 1 17 15 17 1 18 15 18 2 |